Dutch cancer patients to benefit from Erasmus Medical Center’s new treatment technology
Largest medical center in the Netherlands upgrades with several Elekta Versa HD linear accelerators
ROTTERDAM, the Netherlands, June 2, 2014 /PRNewswire/ — Clinicians at the Erasmus University Medical Center (Erasmus MC) in Rotterdam, the Netherlands, will be able to offer patients the most modern cancer treatment available through its purchase of Elekta Versa HD(TM) linear accelerators (linacs) and a substantial software upgrade including Elekta’s MOSAIQ® oncology information system and Monaco® 5 treatment planning system.
The advanced Versa HD linac system is designed to improve patient care and treat a broad spectrum of cancers. Its high precision and unique beam shaping technology increases tumor targeting, with the aim of delivering better outcomes for cancer patients.
According to Comprehensive Cancer Centre the Netherlands (IKNL), approximately 100,000 people are diagnosed with cancer in the Netherlands annually. Many of them are treated at Erasmus MC, which will receive new linacs, while those at Albert Schweitzer hospital, a satellite in Dordrecht, will be upgraded.
Luca Incrocci, Associate Professor of Radiation Oncology at Erasmus MC, says: “Our history of research and collaboration with Elekta means we know we are receiving commitment and quality. Elekta’s equipment and solutions will help us to fulfill our vision of being a recognized leader in treating patients with cancer and to meet our goal to develop research programs to improve treatment results and the quality of life of our patients. This will help us to grow into one of the best medical institutes in the world.”
“Erasmus and Elekta have had a collaborative relationship that goes back 10 years,” says Thijs van Bommel, Business Unit Manager for the Netherlands. “They share our pioneering spirit and focus on patient care, education and scientific research. This mindset helped them easily understand the benefits of Elekta solutions including Versa HD, a flexible and integrated treatment system.”
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: email@example.com
Time zone: CET: Central European Time
Raven Canzeri, Global Public Relations Manager, Elekta
Tel: +1 770-670-2524, e-mail: firstname.lastname@example.org
Time zone: ET: Eastern Time
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.